All In Biotech

Drug Trial Radar · NCT04791579

Antibiotic Prophylaxis for Neurogenic Bladder Botox

Prophylactic Antibiotics Following Treatment of Neurogenic Overactive Bladder With Intradetrusor onabotulinumtoxinA for the Reduction of Postoperative UTI: a Randomized Blinded Placebo-controlled Trial

Last checked: Nov 20, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Feb 1, 2025

Primary completion

Mar 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
University of AlbertaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Injection of Botox into the bladder is a procedure used to treat neurogenic overactive bladder at the Dianne and Irving Kipnes Urology Centre in the Kaye Edmonton Clinic. A common complication following bladder Botox is bladder infection. There are no well-studied preventative antibiotics given at the time of bladder Botox for the reduction of post-operative bladder infection. We are proposing a research study that will randomize participants into two groups - one receiving antibiotics and the other receiving placebo pills following bladder Botox. The main goal of our study is to determine if preventative antibiotics at the time of bladder Botox injection reduces post-operative bladder infection. It will provide a valuable learning opportunity for a trainee starting their academic career through working closely with established researchers across two disciplines. We hope the results of our study can ultimately be used to improve outcomes and safety for a common Urologic procedure. In addition, findings from our study could help reduce unnecessary use of antibiotics resulting in cost savings in the health care system and reduction in the risk of antibiotic resistance.

Conditions

  • Neurogenic Bladder
  • Post-operative Urinary Tract Infections

Interventions

  • CiprofloxacinDrug

    Fluoroquinolone antibiotic

  • PlaceboDrug

    Placebo pill

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Postoperative Urinary Tract InfectionTime frame: 2 weeks following the procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Alberta

    Edmonton, Alberta, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.